search
Back to results

Cognitive Rehabilitation in Post-COVID-19 Condition (TRAINCOVID)

Primary Purpose

COVID-19

Status
Recruiting
Phase
Not Applicable
Locations
Norway
Study Type
Interventional
Intervention
Goal Management Training (GMT)
Sponsored by
Lovisenberg Diakonale Hospital
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for COVID-19 focused on measuring Rehabilitation

Eligibility Criteria

18 Years - 65 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • history of laboratory- or home-test confirmed, SARS-CoV-2 infection (> 3 months since infection)
  • perceived cognitive difficulties (attention, memory, EF) affecting everyday functioning that have lasted for at least two months and that cannot be explained by an alternative diagnosis
  • age between 18-65 years

Exclusion Criteria:

  • ongoing alcohol- or substance abuse, premorbid insult and/or comorbid neurological disease, severe neurocognitive problems interfering with the capacity to participate, sensory disorders biasing cognitive assessment, psychotic disorders, lack of proficiency in Norwegian, and being previously enrolled in a GMT trial.

Sites / Locations

  • Lovisenberg Diaconal HospitalRecruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

No Intervention

Arm Label

Goal Management Training (GMT)

Wait list

Arm Description

Internet-delivered group-based GMT to groups of six participants in six two-hour sessions delivered weekly (five weeks). Manualized intervention.

Wait list control condition

Outcomes

Primary Outcome Measures

The Metacognition Index from the Behavior Rating Inventory of Executive Function - Adult Version (BRIEF-A)
Self-report measure of daily life executive function (metacognition). Range:70-210. Higher score indicate greater executive dysfunction.

Secondary Outcome Measures

The Behaviour regulation Index from Behavior Rating Inventory of Executive Function - Adult Version (BRIEF-A)
Self-report measure of daily life executive function (behaviour regulation). Range: 70-210. Higher score indicate greater executive dysfunction.
Cambridge Neuropsychological Test Automated Battery (CANTAB), subtests: the Stop Signal Task, Spatial Working Memory, Intra-Extra Dimensional Set Shift and Rapid Visual Information Processing
Performance-based neurocognitive test battery
The Hospital Anxiety and Depression Scale
Self-report measure of symptoms of anxiety and depression. The maximum score is 21 for depression and 21 for anxiety, range 0-21 on each scale. A higher score = more symptoms.
The Generalized Self-Efficacy Scale
Self-report measure of self-efficacy. Range:10-40. Higher score indicate higher self-efficacy.
Fatigue Severity Scale
Self-report measure of fatigue. 7 items. Range 7-49. Higher score indicate more fatigue.
The Perceived Deficits Questionnaire
Self-report measure of daily-life cognitive difficulties. The total score range from 0 to 80, with a higher score indicating greater perceived cognitive impairment.
Everyday Memory Questionnaire
Self-report measure of daily-life cognitive difficulties. The total score range from 0 to 52, with a higher score indicating greater perceived cognitive impairment.
RAND 12-Item Health Survey (RAND-12)
Self-report measure of quality of life. Range 0-10; a high score defines a more favorable health state.
EuroQol five-dimension scale questionnaire (EQ-5D)
Self-report measure of quality of life. The range of the EQ-5D index scores is 0 to 1 (1 indicates the best health state), but negative scores as low as-0.59 are possible for health states deemed to be worse than death.
DUKE-UNC Functional Social Support Questionnaire (FSSQ)
Self-report measure of social support. 8 items. The total score range from 8 to 40. Higher score indicates more social support.
DePaul Symptom Questionnaire short version
Self-report measure of fatigue symptoms. 14 items. The total score range from 0 to 56 for both frequency and severity for each item.
The Resilience Scale for Adults
Self-report measure of resilience. 33 items. The total score range from 33 to 165

Full Information

First Posted
August 9, 2022
Last Updated
September 8, 2023
Sponsor
Lovisenberg Diakonale Hospital
Collaborators
University of Oslo, Icahn School of Medicine at Mount Sinai, University of Toronto, UiT The Arctic University of Norway, Oslo University Hospital
search

1. Study Identification

Unique Protocol Identification Number
NCT05494424
Brief Title
Cognitive Rehabilitation in Post-COVID-19 Condition
Acronym
TRAINCOVID
Official Title
Cognitive Rehabilitation in Post-COVID-19 Condition: A Study Protocol for a Randomized Controlled Trial
Study Type
Interventional

2. Study Status

Record Verification Date
September 2023
Overall Recruitment Status
Recruiting
Study Start Date
September 8, 2023 (Actual)
Primary Completion Date
July 2024 (Anticipated)
Study Completion Date
January 2029 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Lovisenberg Diakonale Hospital
Collaborators
University of Oslo, Icahn School of Medicine at Mount Sinai, University of Toronto, UiT The Arctic University of Norway, Oslo University Hospital

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No

5. Study Description

Brief Summary
Post-COVID-19 condition is frequently comprised of persistent cognitive sequela, including deficits in attention and executive functions (EFs). Goal Management Training (GMT) is a cognitive rehabilitation (CR) intervention for improving attention and EFs that has received empirical support in studies of other patient groups. The present study aims to determine the efficacy of GMT for improving everyday attention and EFs in adults who experience persistent cognitive deficits after COVID-19. The study is a randomized controlled trial (RCT), comparing the efficacy of GMT to a wait list control condition (WL), for improving persistent cognitive sequela in post-COVID-19 condition. The study aims to recruit 240 participants aged 18 to 65 years with a history of laboratory- or home-test confirmed, SARS-CoV-2 infection (> 3 months since infection) and perceived attentional and EF difficulties in daily life that have lasted for at least two months and that cannot be explained by an alternative diagnosis. Participants will be randomized to either group-based GMT (n = 120) or WL (n = 120). GMT will be internet-delivered to groups of six participants in six two-hour sessions delivered weekly (five weeks). The primary outcome will be the Metacognition Index of the Behavior Rating Inventory of Executive Function - Adult Version, a self-report measure assessing everyday EF difficulties, at six months post-treatment. Secondary outcomes include performance-based neurocognitive measures and rating scales of cognition, emotional health, quality of life, and fatigue. Secondary aims include to explore to what extent potential early change predicts outcome, and to examine what characterize those who profit from GMT, in addition to describe the neurocognitive and emotional health in a Covid-19 sample. The investigators will also examine potential effects of GMT at 2- and 5-year follow-up.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
COVID-19
Keywords
Rehabilitation

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
Outcomes Assessor
Allocation
Randomized
Enrollment
240 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Goal Management Training (GMT)
Arm Type
Experimental
Arm Description
Internet-delivered group-based GMT to groups of six participants in six two-hour sessions delivered weekly (five weeks). Manualized intervention.
Arm Title
Wait list
Arm Type
No Intervention
Arm Description
Wait list control condition
Intervention Type
Behavioral
Intervention Name(s)
Goal Management Training (GMT)
Other Intervention Name(s)
GMT
Intervention Description
Goal Management Training is a cognitive rehabilitation intervention that relies on metacognitive strategies to reengage top-down attention processes, in addition to teaching problem-solving techniques, attempting to address executive dysfunctions.
Primary Outcome Measure Information:
Title
The Metacognition Index from the Behavior Rating Inventory of Executive Function - Adult Version (BRIEF-A)
Description
Self-report measure of daily life executive function (metacognition). Range:70-210. Higher score indicate greater executive dysfunction.
Time Frame
Change from baseline up to 6 months
Secondary Outcome Measure Information:
Title
The Behaviour regulation Index from Behavior Rating Inventory of Executive Function - Adult Version (BRIEF-A)
Description
Self-report measure of daily life executive function (behaviour regulation). Range: 70-210. Higher score indicate greater executive dysfunction.
Time Frame
Change from baseline up to 6 months
Title
Cambridge Neuropsychological Test Automated Battery (CANTAB), subtests: the Stop Signal Task, Spatial Working Memory, Intra-Extra Dimensional Set Shift and Rapid Visual Information Processing
Description
Performance-based neurocognitive test battery
Time Frame
Change from baseline up to 6 months
Title
The Hospital Anxiety and Depression Scale
Description
Self-report measure of symptoms of anxiety and depression. The maximum score is 21 for depression and 21 for anxiety, range 0-21 on each scale. A higher score = more symptoms.
Time Frame
Change from baseline up to 6 months
Title
The Generalized Self-Efficacy Scale
Description
Self-report measure of self-efficacy. Range:10-40. Higher score indicate higher self-efficacy.
Time Frame
Change from baseline up to 6 months
Title
Fatigue Severity Scale
Description
Self-report measure of fatigue. 7 items. Range 7-49. Higher score indicate more fatigue.
Time Frame
Change from baseline up to 6 months
Title
The Perceived Deficits Questionnaire
Description
Self-report measure of daily-life cognitive difficulties. The total score range from 0 to 80, with a higher score indicating greater perceived cognitive impairment.
Time Frame
Change from baseline up to 6 months
Title
Everyday Memory Questionnaire
Description
Self-report measure of daily-life cognitive difficulties. The total score range from 0 to 52, with a higher score indicating greater perceived cognitive impairment.
Time Frame
Change from baseline up to 6 months
Title
RAND 12-Item Health Survey (RAND-12)
Description
Self-report measure of quality of life. Range 0-10; a high score defines a more favorable health state.
Time Frame
Change from baseline up to 6 months
Title
EuroQol five-dimension scale questionnaire (EQ-5D)
Description
Self-report measure of quality of life. The range of the EQ-5D index scores is 0 to 1 (1 indicates the best health state), but negative scores as low as-0.59 are possible for health states deemed to be worse than death.
Time Frame
Change from baseline up to 6 months
Title
DUKE-UNC Functional Social Support Questionnaire (FSSQ)
Description
Self-report measure of social support. 8 items. The total score range from 8 to 40. Higher score indicates more social support.
Time Frame
Change from baseline up to 6 months
Title
DePaul Symptom Questionnaire short version
Description
Self-report measure of fatigue symptoms. 14 items. The total score range from 0 to 56 for both frequency and severity for each item.
Time Frame
Change from baseline up to 6 months
Title
The Resilience Scale for Adults
Description
Self-report measure of resilience. 33 items. The total score range from 33 to 165
Time Frame
Change from baseline up to 6 months

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
65 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: history of laboratory- or home-test confirmed, SARS-CoV-2 infection (> 3 months since infection) perceived cognitive difficulties (attention, memory, EF) affecting everyday functioning that have lasted for at least two months and that cannot be explained by an alternative diagnosis age between 18-65 years Exclusion Criteria: ongoing alcohol- or substance abuse, premorbid insult and/or comorbid neurological disease, severe neurocognitive problems interfering with the capacity to participate, sensory disorders biasing cognitive assessment, psychotic disorders, lack of proficiency in Norwegian, and being previously enrolled in a GMT trial.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Head of Research at Lovisenberg Hospital
Phone
(+47) 95033144
Email
anners.lerdal@lds.no
First Name & Middle Initial & Last Name or Official Title & Degree
Sofie Buer
Phone
(+47) 92640011
Email
sofiebuer93@outlook.com
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Jan Stubberud, PhD
Organizational Affiliation
University of Oslo and Lovisenberg Hospital
Official's Role
Principal Investigator
Facility Information:
Facility Name
Lovisenberg Diaconal Hospital
City
Oslo
Country
Norway
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Anners Lerdal
Email
anners.lerdal@lds.no

12. IPD Sharing Statement

Plan to Share IPD
No
Citations:
PubMed Identifier
36208718
Citation
Hagen BI, Lerdal A, Soraas A, Landro NI, Bo R, Smastuen MC, Becker J, Stubberud J. Cognitive rehabilitation in post-COVID-19 condition: A study protocol for a randomized controlled trial. Contemp Clin Trials. 2022 Nov;122:106955. doi: 10.1016/j.cct.2022.106955. Epub 2022 Oct 5.
Results Reference
derived

Learn more about this trial

Cognitive Rehabilitation in Post-COVID-19 Condition

We'll reach out to this number within 24 hrs